|
||||||||||||||||||||||
|
|
Alternate Title Phase II Randomized Chemoprevention Study of Iloprost in Patients at High Risk for Lung Cancer
Special Category: SPORE trial Trial Description Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned to one of two groups. Patients in group one will receive iloprost by mouth twice a day for up to 6 months. Patients in group two will receive a placebo by mouth twice a day for up to 6 months. Patients will be evaluated at 1 month and once a year thereafter. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations University of Colorado Cancer Center at UC Health Sciences Center
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |